Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anne-Marie Asemissen

Showing results (1-10 of 24) with videos related to

Pageof 3
Sort By:
Cancer Immunology, Immunotherapy : CII|April 11, 2009
Vaccination strategies in patients with renal cell carcinomaAnne Marie Asemissen, Peter Brossart
Computer Methods and Programs in Biomedicine|December 18, 2024
Transferable automatic hematological cell classification: Overcoming data limitations with self-supervised learningLaura Wenderoth, Anne-Marie Asemissen, Franziska Modemann, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|March 15, 2006
Specific central memory T cells in the bone marrow of patients immunized against tyrosinase peptidesAnne Letsch, Ulrich Keilholz, Florian Kern, et al.
Seminars in Cancer Biology|March 6, 2004
Rational peptide-based tumour vaccine development and T cell monitoringCarmen Scheibenbogen, Anne Letsch, Alexander Schmittel, et al.
The Journal of Investigative Dermatology|April 17, 2004
Functional CCR9 expression is associated with small intestinal metastasisAnne Letsch, Ulrich Keilholz, Dirk Schadendorf, et al.
Tumori|April 3, 2019
Fulminant blast crisis with de novo 11q23 rearrangement in a Philadelphia-positive CML patient undergoing treatment with dasatinibSnjezana Janjetovic, Anne Marie Asemissen, Frank Dicker, et al.
International Journal of Cancer|January 13, 2005
Peptide vaccination after repeated resection of metastases can induce a prolonged relapse-free interval in melanoma patientsAnne Letsch, Ulrich Keilholz, Michael Fluck, et al.
Oncology|March 27, 2009
Sunitinib treatment for patients with advanced clear-cell renal-cell carcinoma after progression on sorafenibKaja Zimmermann, Alexander Schmittel, Ursula Steiner, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 27, 2005
Addition of histamine to interleukin 2 treatment augments type 1 T-cell responses in patients with melanoma in vivo: immunologic results from a randomized clinical trial of interleukin 2 with or without histamine (MP 104)Anne Marie Asemissen, Carmen Scheibenbogen, Anne Letsch, et al.
Cancer Immunology, Immunotherapy : CII|July 20, 2006
Addition of GM-CSF to a peptide/KLH vaccine results in increased frequencies of CXCR3-expressing KLH-specific T cellsIl-Kang Na, Ulrich Keilholz, Anne Letsch, et al.
Pageof 3

Showing results (1-10 of 24) with videos related to

Sort By:
Pageof 3
Cancer Immunology, Immunotherapy : CII|April 11, 2009
Vaccination strategies in patients with renal cell carcinomaAnne Marie Asemissen, Peter Brossart
Computer Methods and Programs in Biomedicine|December 18, 2024
Transferable automatic hematological cell classification: Overcoming data limitations with self-supervised learningLaura Wenderoth, Anne-Marie Asemissen, Franziska Modemann, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|March 15, 2006
Specific central memory T cells in the bone marrow of patients immunized against tyrosinase peptidesAnne Letsch, Ulrich Keilholz, Florian Kern, et al.
Seminars in Cancer Biology|March 6, 2004
Rational peptide-based tumour vaccine development and T cell monitoringCarmen Scheibenbogen, Anne Letsch, Alexander Schmittel, et al.
The Journal of Investigative Dermatology|April 17, 2004
Functional CCR9 expression is associated with small intestinal metastasisAnne Letsch, Ulrich Keilholz, Dirk Schadendorf, et al.
Tumori|April 3, 2019
Fulminant blast crisis with de novo 11q23 rearrangement in a Philadelphia-positive CML patient undergoing treatment with dasatinibSnjezana Janjetovic, Anne Marie Asemissen, Frank Dicker, et al.
International Journal of Cancer|January 13, 2005
Peptide vaccination after repeated resection of metastases can induce a prolonged relapse-free interval in melanoma patientsAnne Letsch, Ulrich Keilholz, Michael Fluck, et al.
Oncology|March 27, 2009
Sunitinib treatment for patients with advanced clear-cell renal-cell carcinoma after progression on sorafenibKaja Zimmermann, Alexander Schmittel, Ursula Steiner, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 27, 2005
Addition of histamine to interleukin 2 treatment augments type 1 T-cell responses in patients with melanoma in vivo: immunologic results from a randomized clinical trial of interleukin 2 with or without histamine (MP 104)Anne Marie Asemissen, Carmen Scheibenbogen, Anne Letsch, et al.
Cancer Immunology, Immunotherapy : CII|July 20, 2006
Addition of GM-CSF to a peptide/KLH vaccine results in increased frequencies of CXCR3-expressing KLH-specific T cellsIl-Kang Na, Ulrich Keilholz, Anne Letsch, et al.
Pageof 3